drugset / Trial / NCT06751199

UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes

NCT06751199

Recruiting 16 enrolled Shanghai Changzheng Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim is to Investigate the safety and efficacy of Portal vein infusion Allogeneic Human umbilical cord mesenchymal stem cells combined with Allogeneic islet transplantation for the treatment of diabetes

Timeline

Start
2024-12-30
Primary completion
2026-07-30
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject allogeneic islet Cell therapy Other
Subject human umbilical cord mesenchymal stem cells Cell therapy Other

Indications